Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517595
Status:
COMPLETED
Last Update Posted:
2012-03-12
First Post:
2007-08-16
Brief Title:
Phase II Study Alimta and Gemzar Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIBIV NSCLC
Sponsor:
Accelerated Community Oncology Research Network
Organization:
Accelerated Community Oncology Research Network
Study Overview
Official Title:
A Phase II Study of Pemetrexed and Gemcitabine Plus Bevacizumab as First Line Chemotherapy for Elderly Patients With Stage IIIBIV Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to determine the progression free survival with pemetrexed and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage IIIBIV non-small cell lung cancer NSCLC
The secondary objectives are to determine the overall response rate overall survival chemotherapy induced toxicity profile of this combination time to progression and patient reported symptom burden
The secondary objectives are to determine the overall response rate overall survival chemotherapy induced toxicity profile of this combination time to progression and patient reported symptom burden
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None